Alpha Cognition Inc. Common Stock (ACOG) is a publicly traded company in the Financial Services sector, operating within the Financial - Conglomerates industry. The company is headquartered in Vancouver, BC, Canada. The current CEO is Michael E. McFadden.
ACOG has IPO date of 2024-11-12, 5 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $102.82M.
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
